Tag Archives: HEA

PR Newswire

Dada Group secures necessities supply in Shijiazhuang during COVID-19 outbreak — Chinese National TV Reported

Leave a comment

SHANGHAI, Jan. 25, 2021 — Dada Group (Nasdaq: DADA) ("Dada" or the "Company"), China’s leading local on-demand delivery and retail platform, is working with retailers and brands to provide safe, contactless on-demand delivery service in Shijiazhuang, Hebei Province, to combat with the latest COVID-19 outbreak. Recently, thousands of Dada Now riders in Shijiazhuang worked flat out to ensure the stable supply of daily necessities to residents. Their efforts were reported by Chinese National TV, and other mainstream media across the country.

Dada Now riders in Shijiazhuang
Dada Now riders in Shijiazhuang

According to National TV’s coverage, in accordance with the requirements of the local governments, Shijiazhuang’s supermarkets suspended offline operations and transferred to online business, which taking online orders and providing contactless delivery, to ensure the people’s daily necessities while staying home. During the lockdown period, riders of Dada Now, Dada Group’s on-demand delivery platform, were working to deliver daily necessities from supermarkets to the residents. Peng Sun is one of these Dada Now riders.

Since the latest COVID-19 ourbreak in Shijiazhuang, Peng Sun took a second nucleic acid test required by Dada Now platform. After receiving the healthy result on the second day, he started to deliver daily necessities to residents. As supermarket O2O business adopted by increasing number of consumers, delivery orders grew exponentially. He worked tirelessly to deliver products everyday: "I was on my way even at late 10 p.m. I am proud of myself, because I contribute to fight against COVID-19."

Dada Group is one of 51 necessities supply enterprises guaranteed and recommended by Shijiazhuang government. JDDJ and Dada Now have played a kay role in ensuring daily supply and safe delivery. On January 11, JDDJ collaborated with nearly 20 supermarket chains in Shijiazhuang, including Beiguo Supermarket, Yonghui Supermarket, CR Vanguard and Olé, as well as local pharmacies including Shiyao Pharmacy, Hebei Lerentang Pharmacy and Shineway Pharmacy, to guarantee the daily supply of living products.

At the same time, Dada Now launched the emergency measures, opened a green channel for delivery riders to appeal abnormal situations, and extended the delivery time. The platform also launched its contactless delivery service and riders’ health code authentication, while arranging secondary nucleic acid testing for riders and providing them with disinfectant, masks and other epidemic prevention equipment to ensure the safety of riders, merchants and consumers. Besides, Dada Now also required riders to wear masks and disinfection protection during the delivery through the Dada Now’s Rider Application and the Wechat groups.

In January, Dada Group announced that Dada Now and JDDJ would stay open during Chinese New Year in February. And the two platforms will maintain safety measures to ensure stable and quick services.

About Dada Group

Dada Group is a leading platform of local on-demand retail and delivery in China. It operates JDDJ, one of China’s largest local on-demand retail platforms for retailers and brand owners, and Dada Now, a leading local on-demand delivery platform open to merchants and individual senders across various industries and product categories. The Company’s two platforms are inter-connected and mutually beneficial. The Dada Now platform enables improved delivery experience for participants on the JDDJ platform through its readily accessible fulfillment solutions and strong on-demand delivery infrastructure. Meanwhile, the vast volume of on-demand delivery orders from the JDDJ platform increases order volume and density for the Dada Now platform. In June 2020, Dada Group began trading on the Nasdaq Global Market, under the ticker symbol "DADA."

Related Links :

http://imdada.cn

PR Newswire

New Zealand team creates world-first innovation in the fight against Coronavirus

Leave a comment

AUCKLAND, New Zealand, Jan. 23, 2021 — Datamine, a New Zealand based AI company, has created ëlarm: a personal early warning indicator for viral infection, including Coronavirus. The ëlarm system overcomes what is arguably our greatest obstacle – viral spread by asymptomatic people who do not know they are infectious. By developing personal baselines of biometric data from smartphones and other wearables (such as Fitbit, Apple Watch and Samsung), ëlarm detects changes to those individual baselines that fit COVID-19 patterns – changes that occur as the body begins fighting viral infection.

"With ëlarm, you can know you’re sick before you feel sick," says ëlarm CEO and founding director of Datamine, Paul O’Connor.

Operating in New Zealand since June 2020, the ëlarm system has been developed to detect Coronavirus cases up to three days before people know they have the lethal virus."Based on our New Zealand success and the extensive data we’ve gathered from clinicians around the world, ëlarm is an accurate predictor of viral symptoms," Mr O’Connor says.

For more information: https://elarm.health/

While ëlarm is not a test and does not provide medical advice, the system alerts users to biometric changes that indicate viral infection and provides relevant World Health Organisation and CDC guidelines. This enables people to proactively get tested and self-isolate before any symptoms appear. This helps prevent the spread of viral infection to loved ones, communities, and workmates.

As opposed to developing technology based on specific smartwatches, ëlarm is ‘device agnostic.’ As a software service, ëlarm can use data from a growing list of wearable devices, and is available worldwide.

"When Covid-19 emerged, we had already created a vault where personal health and wearables data is safely stored and analyzed. We saw that we had the expertise and technology to make a substantial contribution in the fight against Coronavirus," Mr O’Connor explains. "With new Coronavirus strains and possible further mutations, the urgency is to slow the spread of the virus through our global population until a vaccine is available." 

Professor Michael Baker, one of New Zealand’s leading epidemiologists, says there are many useful applications for this technology. "It’s very encouraging that New Zealand is producing exciting innovations of new surveillance tools for tracking people who are potentially infected by Coronavirus and other infectious agents." 

ëlarm is available via the Apple Store and Google Play at www.elarm.health

Related Links :

https://elarm.health/

PR Newswire

MediWelcome Soars 26% in Trading Debut

Leave a comment

Pharmaceutical Giant CSPC Pharma Becomes the Largest Placee Join Forces to Expand Internet Hospital Services

HONG KONG, Jan, 22, 2021 — Mediwelcome Healthcare Management & Technology Inc. ("MediWelcome") commenced trading of its shares on the Main Board of SEHK on 19 Jan, 2021. The stock code of MediWelcome is 2159. Shares of MediWelcome were actively traded and opened at HK$4.00, up 33% against its issue price of HK$3.00. It surged to the day’s high at HK$4.81 before closing at HK$3.79, up 26% over its issue price. Total transaction volume was approximately 101 million shares, with an aggregate turnover of approximately HK$403 million.

CSPC Pharma Becomes the Largest Placee of the International Offering
Co-operation Between the Two Deepened

CSPC Pharmaceutical Group Limited ("CSPC Pharma"; stock code: 1093), a leading pharmaceutical listed company in Hong Kong, has been allotted 8,000,000 shares, representing approximately 32% of 25,000,000 Shares, the final number of Offer Shares under the International Offering, and approximately 4% of total issued share capital upon listing. As a result, CSPC Pharma has become the largest placee of the International Offering.

At the end of 2020, MediWelcome announced a strategic partnership of internet hospital services with CSPC Pharma. They launched a "Stroke Patients Standardised Post-Treatment Management Project" through MediWelcome’s internet hospital platform to provide one-stop post-treatment services, including consultation, visiting, checking, medicine delivery to the stroke patients in China. The project has already launched in Shanghai and Jilin, and will promote to the whole country to create a standardised post-treatment management ecosystem for Chinese stroke patients. Becoming the largest placee, CSPC Pharma undoubtedly shows its confidence in MediWelcome’s execution abilities in internet hospital services. The co-operation between MediWelcome and CSPC Pharma will trigger the Group’s innovation in the new business and will drive the business development of the Group.

Commenting on the positive reception from market in its trading debut, Mr. Shi Wei, Chairman of the Board and Executive Director, said, "The successful listing on SEHK marks a significant milestone of the Company’s business development. I would like to express our deepest gratitude to our investors for their recognition and support. Also, I am grateful for CSPC Pharma joining our International Offering. CSPC Pharma has been our long-term strategic partner. And now it has also become our shareholder, which showed its full trust in MediWelcome. I believe our co-operation will be deepened as CSPC Pharma is one of our shareholders now and will lay a solid foundation for the expansion and the development of our new business, so we will have a broader developmental prospect. The cheering stock performance is the best demonstration of the Company’s capabilities and investors’ confidence. Looking ahead, we will continue our business development at internet hospital services and we will be able to foster sustainable growth with a view to striving for optimal returns for our shareholders."

PR Newswire

Havas Health & You Evolves Network Positioning, Announces Chief Content Officer Hire Lars Bengston, and Launches Content Assembly

Leave a comment

Network hosts launch event, The Future of Health, highlighting insights into industry future, revived mission and new areas of investment

NEW YORK, Jan. 22, 2021 — 2020 was a monumental year for all industries, and an especially formative time for health. The pandemic forced care providers, hospital systems and health brands to adapt and pivot at unprecedented speed and scale, with major industry players leaning into and creating new models by the minute in order to survive. The once-in-a-lifetime transformational events have acted as a catalyst, driving significant, permanent change that will shape a future health environment much different than previously seen.

Amidst rapid growth, Havas Health & You (HH&Y) had planned to evolve their network positioning to focus on what they call "Human Purpose." Amongst recent category history, this positioning is more relevant than ever. Global CEO Donna Murphy states, "People’s lives and families are our key motivating factors every day, no matter where they lie within the health ecosystem. If, through the work that we do, we can make someone feel less isolated, provide peace of mind, or increase quality of life, we’ve done our job. Today marks a new era for our business, a new look and feel for us, an exciting strategic hire, and the founding of a new division of our business."

"Powerful health brands are as much about cheering on the human spirit as they are about treating the human body," says Brian Robinson, Chief Strategy Officer of HH&Y. "Human Purpose is our approach to building brands; that is, creating brands that help people thrive."

HH&Y announced their evolved positioning with a thought leadership event, The Future of Health, providing context to the landscape and expert guidance as we look to the future, featuring several members of their executive leadership team, Eben Shapiro of Time, Aubree Curtis of Creative Artists Agency (CAA), and patients and physicians from around the world.

The event and new positioning were led by both Robinson and Megan Rokosh, Global Chief Marketing Officer, and executed by the Global Marketing team, Havas Production Services and the highly-awarded Havas Lynx. Rokosh states, "Health has entered into the cultural conversation like never before in history over the last year. Health brands of the future need access to a plethora of different skills and expertise. As a partner and industry leader, it’s incumbent on us to provide both. Our new positioning reflects our evolved point of view, the refreshed category vibrancy and the areas of investment and growth that we see being the pillars of the future of health."

These pillars include innovation, technology, medical, customer experience, and content. Industry leader Lars Bengston, who was the co-creator of Some Good News with John Krasinski, Publisher of VICE Media, and Head of Content at Thrive Global, joins as the network’s Chief Content Officer, stating "By creating content that amplifies solutions to today’s HCP and patient challenges, we have the power to rewrite old perceptions, and reimagine traditional methods of communication. Moreover, in today’s world, good content changes lives – and adding value to the culture of the communities you serve has positive and outlasting commercial benefits. We are built to guide you on the new healthcare journey of today, one that incorporates the human spirit as our guiding point."

The newly formed division, the Content Assembly, will blend storytelling with HH&Y’s leading practices in data, technology and customer experience, and will be a global collection of leading creators and strategists from across industries led by Bengston and Rokosh.

You can view The Future of Health https://havas.6connex.com/event/futureofhealth/login.

About Havas Health & You:
Havas Health & You unites Havas Life, Health4Brands (H4B), Lynx, Havas Life PR and Havas Health Plus, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Group. Its customer-centric approach has the talent, tenacity and technology that health-and-wellness companies, brands and people need to thrive in today’s world. For more information, go to www.HavasHealthandYou.com

Logo – https://techent.tv/wp-content/uploads/2021/01/havas-health-you-evolves-network-positioning-announces-chief-content-officer-hire-lars-bengston-and-launches-content-assembly.jpg  

Related Links :

http://www.havashealthandyou.com

PR Newswire

Medibio Granted CE Mark Approval for MEBsleep

Leave a comment

MINNEAPOLIS, Jan. 19, 2021 — Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF), is pleased to announce that it has received CE Mark approval for its sleep staging software, MEBsleep.

MEBsleep is a software-only medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. MEBsleep uses artificial intelligence, deep learning algorithms and neural network methodology to analyse large amounts of raw data, including autonomic nervous system modulation throughout sleep stages, to highlight key information to assist the physician in understanding the patient’s condition.

Currently, the gold standard for identifying sleep stages in a sleep laboratory setting is a 60 to 90 minute visual assessment conducted by a clinician. MEBsleep performs the same assessment in 60 to 90 seconds, thereby providing improved efficacy for overall patient evaluation by sleep medicine technicians, under the supervision of a physician.

CE Mark approval will allow Medibio to commercialise MEBsleep across the European Economic Community. The intended users of this device are sleep technicians and researchers. The path is now clear for Medibio to accelerate its commercialization activities for MEBsleep in the EEC. The company is currently exploring commercialization paths with European academic groups and pharma companies focused on behavioural sleep medicine.

Claude Solitario, Managing Director of Medibio, said the approval was a significant regulatory milestone.

"MEBsleep is our first marketable product with CE Mark and its approval is an important step on our path towards commercialisation. Furthermore, it is also an important validation as we advance development of our depressive burden software medical device MEB-001, of which MEBsleep is a component," said Mr Solitario.

The prevalence of sleep disorders, such as insomnia, sleep apnea, and Restless Leg Syndrome, has increased appreciably in recent years, as has general awareness of their debilitating effects. Consequently, the global market for sleep aids, which was valued at US$71billion in 2018, is forecasted to grow at a compound annual rate of 7% between 2019 and 2025[1]. Europe and North America together account for more than 65% of total sales of sleep aids globally, with the United States, Germany, and the UK among the top markets. 

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental wellbeing solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

PR Newswire

CES 2021 Taiwanese Startup, VitalSigns Technology, Debuting at CES with Remarkable Air Quality Monitoring IoT Device

Leave a comment

TAIPEI, Jan. 19, 2021 — Following its previous successes in bio-signal monitors and connective health, VitalSigns Technology shifted gears and entered the IoT industry with its outstanding biosensor and physiological monitoring development capabilities. Its professional air quality monitoring systems EVMGG2H1 (Femto ampere level) and EVMOP1H1 are the latest products designed to detect and control air quality, helping manufacturers, government agencies, and research institutes collect accurate and useful environmental data.

The professional air quality monitor developed by VitalSigns Technology provides real-time detection of environmental data, including humidity, temperature, PM2.5 with Electron Ionization (Femto ampere level) or Optical type, and toxic gases.
The professional air quality monitor developed by VitalSigns Technology provides real-time detection of environmental data, including humidity, temperature, PM2.5 with Electron Ionization (Femto ampere level) or Optical type, and toxic gases.

Why Air Quality Monitoring Matters

Air pollution is a rising concern worldwide, and environmental hazards are exacerbating the spread of diseases such as asthma, cardiovascular disease, lung cancer, and obstructive pulmonary disease.

The increase in awareness of the negative health effects of polluted air has driven significant new market demand for air quality monitoring. The estimated value of the air quality monitoring systems market was $4.76 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.26%, according to Infoholic Research.

One Step forward toward the Smart City of Tomorrow

The professional air quality monitor developed by VitalSigns Technology provides real-time detection of environmental data, including humidity, temperature, PM2.5 with Electron Ionization (Femto ampere level) or Optical type, and toxic gases. The system passed the measurement service assessment conducted by the Industrial Technology Research Institute, a national accreditation body (NAB) in Taiwan, at a 95% coefficient of determination.

Product reliability is important for smart city IoT devices that are required to withstand long operating hours. The VitalSigns system features a thorough power management system as well as a fine-particulate ventilation system, waterproof casing, electricity leakage prevention system, unique shelter design, and a fall-down detector to optimize usage in a variety of locations and conditions.

As for data collection connectivity, VitalSigns uses an LTE module instead of less stable connection methods like Wi-Fi and BLE. In addition, the frequency of data transfer to customers’ IoT platforms is customizable. To avoid any possible data loss due to system crash or poor internet connectivity, VitalSigns’ Real-Time Air Quality Monitor’s remedial measures store data onsite for at least 7 days using a built-in 4GBS flash memory.

To suit different needs and missions, VitalSigns uses Femto ampere sensing technology in its electron impact ionization sensors to measure particulate matter in gas. Furthermore, VitalSigns also provides particular toxic gas sensing solutions that have 24-bit high accuracy gas-detect ADC with Android APP and Wireless BLE 4.2 support.

Improving Wellbeing from a Technology Perspective

The key team members of VitalSigns have decades of experience developing high-accuracy ADC systems and biosensors at major IC design companies, including MediaTek and RichTek.

VitalSigns CEO JL Juang remarked that "Our goal is to keep improving healthcare quality and environmental quality for everyone." The company’s consistent investment in research and development related to high-precision devices, IoT, and big data analytics clinched the decision by Taiwan Tech Arena (TTA) to select VitalSigns to be part of the 100 featured Taiwanese startups showcased at CES 2021.

CES 2021 TTA-VR Pavilion: https://pse.is/3bqfyr

PR Newswire

COVID-19 vaccines: Common solution, not competition

Leave a comment

BEIJING, Jan. 15, 2021 — A news report by China.org.cn on China’s COVID-19 vaccines:

 

At the end of 2020, one of China’s self-developed COVID-19 vaccines was granted conditional approval for general use by the National Medical Products Administration. Previously, the United Arab Emirates and Bahrain had already greenlit the vaccine. After China’s official approval, over a dozen countries from different continents signed purchase agreements with China for the vaccine.

Since the initial outbreak, scientists around the world have been working to develop an effective vaccine. Various approaches have been adopted, such as mRNA vaccines, inactivated vaccines and adenovirus vector vaccines. The mRNA vaccine jointly developed by Pfizer and BioNTech was approved in the U.K. and U.S. in December 2020. The adenovirus vector vaccine developed by Oxford-AstraZeneca has not long since been rolled out. China’s recently approved vaccine is inactivated, which is a mature technique, thus making it relatively safe. Without special requirements for transportation or storage, the vaccine’s cost is lower, meaning it is more affordable.

Recent news on the virus mutating makes achieving herd immunity via vaccination all the more important. As such, the Chinese government has promised to provide vaccines free of charge to all Chinese people.

The approval and future use of China’s inactivated vaccine has been made possible only through international cooperation. The phase 3 clinical trials, for instance, were conducted in countries including the UAE and Argentina. Now China is speeding up vaccine production, working to make them a global public good, while being more accessible and affordable. In the future, China will actively provide vaccines to developing countries, including through donations, which is in line with China’s joining of COVAX.

Many foreign media outlets have continued to link vaccine development with political purposes, and have disparaged China’s vaccines. In fact, research and development into COVID-19 vaccines is not a case of companies or countries competing against one another. Faced with the virus, humanity should work together to seek solutions to this common challenge.

Any effective vaccine would mark a victory for global public health and all humanity. China will continue to work with other countries on vaccine development, share knowledge and experience in fighting the pandemic, and overcome the challenge.

China Mosaic
http://www.china.org.cn/video/node_7230027.htm
COVID-19 vaccines: Common solution, not competition
http://www.china.org.cn/video/2021-01/15/content_77119558.htm

Related Links :

http://www.china.org.cn

PR Newswire

CES 2021 Taiwanese Startup ACSI Gives New Technological Shine to Traditional Chinese Medical Treatments

Leave a comment

TAIPEI, Jan. 15, 2021 — Chinese medicine has been receiving increased attention worldwide. These traditional therapeutic treatments are now being combined with modern technology and integrated into Western medicine. Acupuncture, for example, is being widely adopted and trusted by patients and doctors. However, more serious but rarer side effects of acupuncture have also been observed to occur, including collapsed lung (pneumothorax), which accounts for 1.5% of incidents. Thus, a more precise and safer method is being introduced by Advanced Control & System Integration Laboratory (ACSI) under the Handheld Automatic Acupuncture System (HAAS) project, according to Taiwan Tech Arena.

HAAS is a handheld, AI-enabled device that identifies acupoints and positioning using AI image recognition technology.
HAAS is a handheld, AI-enabled device that identifies acupoints and positioning using AI image recognition technology.

Technology Is No Longer Limited to Western Medicine

HAAS is a handheld, AI-enabled device that identifies acupoints and positioning using AI image recognition technology. This makes acupuncture significantly safer than before. In addition, HAAS automatically identifies suitable acupoints for different symptoms based on AI decision making and big data.

Furthermore, HAAS is equipped with different acupoint stimulation modules. The acupuncture module autonomously drops needles to stimulate acupoint positions and provide real-time acupuncture according to the user’s symptoms. The physiotherapy module covers techniques such as moxibustion, the massage gun, and far infrared. This product not only provides more convenient, independent treatment and rapid health recovery effects to achieve personal health care assistance but also provides professional traditional Chinese medicine education assistive devices.

Using HAAS is simple and straightforward. First, after entering the symptoms or acupoints into the mobile app, the AI system confirms the user’s requirements and identifies the acupoints automatically. Simply by operating the device in accordance with the HMI instructions on phone, HAAS will treat the body with AI-controlled acupoint stimulation.

Research results show that both patients and healthy individuals may experience enhanced self-immunity functions and improved symptoms (or even full recovery to health) after treatment with HAAS.

A Steadily Growing, Worldwide Market

The traditional Chinese medicine (TCM) market in China is growing steadily and is expected to reach $844 billion RMB (US$123 billion) in revenue by 2023.

In May 2019, the United Nations World Health Organization (WHO) included traditional Chinese medicine (TCM) in the Global Medical Outline of Diseases ICD for the first time. Since then, TCM has received growing attention in many Western countries, with an increasing number of researchers and clinicians devoting themselves to TCM research.

Innovative Cross-field Applications Are in the DNA of Startups

Advanced Control and System Integration (ACSI) Laboratory is a professional artificial intelligence vision solutions provider. ACSI has over 7 years of experience in the development of vision-based biomedical engineering, advanced driving assistance systems (ADAS), autonomous cars, embedded system technologies, and proprietary high-performance mechatronics solutions. ACSI is dedicated to creating innovation value through the development of TCM-related and adjacent technologies and autonomous cars and by identifying the needs of emerging-market customers.

They have also developed many advanced driver assistance systems (ADAS) and vehicle dynamic controls, focusing on control algorithm development and deployment, including various methods based in nonlinear control theory, robust optimal control, predictive control, machine learning, artificial intelligence, reinforcement learning for vehicle dynamic control systems, adaptive cruise control systems, and adaptive collaborative vehicle control systems.

Its previous success in hardware has helped ACSI develop cross-field applications such as HAAS. This innovative and interesting product has been selected by Taiwan Tech Arena (TTA) as one of the 100 featured Taiwanese startups showcased at CES 2021.

CES 2021 TTA – VR Pavilion：https://pse.is/39znlv

PR Newswire

HRH Prince Mohammed bin Salman announces THE LINE at NEOM

Leave a comment

A revolution in urban living

– Free of cars and streets, residents will have nature and all daily needs within a five-minute walk

– To create 380,000 jobs of the future and contribute SAR 180bn ($48bn) to GDP by 2030

– 170km linear development of hyper-connected AI-enabled communities powered by 100% clean energy 

RIYADH, Saudi Arabia, Jan. 11, 2021 PRNewswire/ — His Royal Highness Mohammed bin Salman, Crown Prince and Chairman of the NEOM Company Board of Directors, today announced THE LINE, a revolution in urban living at NEOM, and a blueprint for how people and planet can co-exist in harmony.


THE LINE, a 170km belt of hyper-connected future communities, without cars and roads and built around nature, is a direct response to some of the most pressing challenges facing humanity today such as legacy infrastructure, pollution, traffic, and human congestion.

A cornerstone of Saudi Vision 2030 and an economic engine for the Kingdom, it will drive diversification and aims to contribute 380,000 jobs of the future and SAR180 billion (USD48 bn) to domestic GDP by 2030.

His Royal Highness said: "Throughout history, cities were built to protect their citizens. After the Industrial Revolution, cities prioritized machines, cars and factories over people. In cities that are viewed as the world’s most advanced, people spend years of their lives commuting. By 2050, commute durations will double. By 2050, one billion people will have to relocate due to rising CO2 emissions and sea levels. 90% of people breathe polluted air. Why should we sacrifice nature for the sake of development? Why should seven million people die every year because of pollution? Why should we lose one million people every year due to traffic accidents? And why should we accept wasting years of our lives commuting?"

"Therefore, we need to transform the concept of a conventional city into that of a futuristic one," His Royal Highness added. "Today, as the Chairman of the Board of Directors of NEOM, I present to you THE LINE. A city of a million residents with a length of 170 km that preserves 95% of nature within NEOM, with zero cars, zero streets and zero carbon emissions."

THE LINE is the first time in 150 years that a major urban development has been designed around people, not roads. Walkability will define life on THE LINE – all essential daily services, such as schools, medical clinics, leisure facilities, as well as green spaces, will be within a five-minute walk.

Ultra-high-speed transit and autonomous mobility solutions will make travel easier and give residents the opportunity to reclaim time to spend on health and wellbeing. It is expected no journey will be longer than 20 minutes.

THE LINE’s communities will be cognitive, powered by Artificial Intelligence (AI), continuously learning predictive ways to make life easier, creating time for both residents and businesses. An estimated 90% of available data will be harnessed to enhance infrastructure capabilities far beyond the 1% typically utilized in existing smart cities.

Redefining sustainability, THE LINE will comprise carbon-positive urban developments powered by 100% clean energy, providing pollution-free, healthier and more sustainable environments for residents. Mixed-use communities will be built around nature, instead of over it.

NEOM’s sectors of the future, headed by global industry leaders, are already addressing some of the world’s most pressing challenges. They are pioneering a new marketplace for breakthrough innovations and creating opportunities to attract talent, investors and partners to become part of its business ecosystem.

Construction of THE LINE will commence in Q1 of 2021. THE LINE is one of the most complex and challenging infrastructure projects in the world and forms part of extensive development work already underway at NEOM.

NEOM is part of the world-class, diversified portfolio of Saudi Arabia’s Public Investment Fund, one of the largest sovereign wealth funds in the world.

About NEOM

NEOM is an accelerator of human progress and a vision of what a New Future might look like. It is a region in northwest Saudi Arabia on the Red Sea being built from the ground up as a living laboratory – a place where entrepreneurship will chart the course for this New Future. It will be a destination and a home for people who dream big and want to be part of building a new model for exceptional liveability, creating thriving businesses, and reinventing environmental conservation.  

NEOM will be the home and workplace to more than a million residents from around the world. It will include towns and cities, ports and enterprise zones, research centres, sports and entertainment venues, and tourist destinations. As a hub for innovation, entrepreneurs, business leaders and companies will come to research, incubate and commercialize new technologies and enterprises in ground-breaking ways. Residents of NEOM will embody an international ethos and embrace a culture of exploration, risk-taking and diversity – all supported by a progressive law compatible with international norms and conducive to economic growth. 

For further information 

Link to announcement speech – NEOM YouTube Channel

Email media@NEOM.com or visit www.NEOM.com, https://newsroom.neom.com/ and https://whatistheline-newsroom.neom.com/ 

Info – https://techent.tv/wp-content/uploads/2021/01/hrh-prince-mohammed-bin-salman-announces-the-line-at-neom.jpg

Logo – https://techent.tv/wp-content/uploads/2021/01/hrh-prince-mohammed-bin-salman-announces-the-line-at-neom-2.jpg

Related Links :

http://www.NEOM.com

PR Newswire

Appian Selected by Accenture as a Core Partner in the INTIENT Network for Life Sciences

Leave a comment

Appian brings low-code speed and automation power to help drive innovation in drug discovery and scientific research

MCLEAN, Va., Jan. 9, 2021 — Appian (NASDAQ: APPN) today announced that it has joined Accenture’s INTIENT partner ecosystem as a core partner. The ecosystem is designed to help independent software vendors (ISVs) and life science companies integrate more effectively to accelerate drug discovery efforts and improve patient outcomes.

The INTIENT Network is an integral part of Accenture’s INTIENT Platform that enables insights and collaboration across the life sciences enterprise to improve productivity, efficiency, and innovation in drug discovery. Accenture has partnered with Appian to integrate low-code development into the INTIENT platform.

The Appian Low-Code Automation Platform allows enterprises to build applications up to 20x faster than traditional code. By providing a single interface that unifies data, process, people and the digital workforce, Appian helps organizations improve digital innovation and optimize business outcomes. Industry leaders trust Appian to improve customer experience, achieve operational excellence, and simplify global risk management and compliance.

"We are proud to work with Accenture to jointly support research, innovation, and better outcomes for the Life Sciences industry," said Marc Wilson, Founder and Senior Vice President of Global Partnerships and Industries at Appian. "Our ability to accelerate business processes, unify enterprise data, and simplify global compliance is why nine of the world’s top 10 drug and biotech organizations use Appian."

As part of the INTIENT partner ecosystem, Appian’s platform can be accessible across the INTIENT product suites.

"Our open partner network is one of the ways we’re bringing innovation to our clients through the Accenture INTIENT Platform," said Jill Schulte, managing director in Accenture’s Life Sciences practice. "Appian’s integration into the INTIENT Platform enables low-code workflow creation and management to accelerate the building of applications for our clients and ultimately for the benefit of their customers and patients."

To learn more about Accenture’s INTIENT Platform, go to https://www.accenture.com/us-en/services/life-sciences/intient

To request a free trial of the Appian Low-code Automation Platform, go to https://www.appian.com/platform/free-trial/.

About Appian
Appian provides a low-code automation platform that accelerates the creation of high-impact business applications. Many of the world’s largest organizations use Appian applications to improve customer experience, achieve operational excellence, and simplify global risk management and compliance. For more information, visit www.appian.com.

Related Links :

http://www.appian.com/